Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

Sebastian Goebel, Juergen H. Prochaska, Lisa Eggebrecht, Ronja Schmitz, Claus Juenger, Heidrun Lamparter, Markus Nagler, Karsten Keller, Meike Coldewey, Sven-Oliver Troebs, Simon Diestelmeier, Soeren Schwuchow-Thonke, Christoph Bickel, Michael Lauterbach, Karl J. Lackner, Hugo ten Cate, Thomas Muenzel, Roland Hardt, Philipp S. Wild*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)

Abstract

Patients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outcome, results were compared with data from individuals receiving specialized care for anti-coagulation (n = 760). Overall, the sample comprised of 813 individuals with HF and 1,160 subjects without HF in the regular care cohort. Quality of OAC assessed by time in therapeutic range (TTR) was 66.1% (47.8%/82.8%) for patients with HF and 70.6% (52.1%/85.9%) for those without HF (p = 0.0046). Stratification for New York Heart Classification (NYHA)-class demonstrated a lower TTR with higher NYHA classes: TTRNYHA-I 69.6% (49.4%/85.6%), TTRNYHA-II 66.5% (50.1%/82.9%) and TTRNYHA->= III 61.8% (43.1%/79.9%). This translated into a worse net clinical benefit outcome for HF (hazard ratio [HR] 1.63 [1.31/2.02]; p <0.0001) and an increased risk of bleeding (HR 1.40 [1.04/1.89]; p = 0.028). Management in a specialized coagulation service resulted in an improvement of all, TTR (+12.5% points), anti-coagulation-specific and non-specific outcome of HF individuals. In conclusion, HF is an independent risk factor for low quality of OAC therapy translating into an increased risk for adverse events, which can be mitigated by specialized care.

Original languageEnglish
Pages (from-to)1930-1939
Number of pages10
JournalThrombosis and Haemostasis
Volume118
Issue number11
DOIs
Publication statusPublished - Nov 2018

Keywords

  • heart failure
  • oral anti-coagulation
  • clinical outcome
  • quality of care
  • health care model
  • THERAPY ANTITHROMBOTIC THERAPY
  • CLINICAL-PRACTICE GUIDELINES
  • ED AMERICAN-COLLEGE
  • ATRIAL-FIBRILLATION
  • ANTICOAGULANT-THERAPY
  • EJECTION FRACTION
  • ADVERSE EVENTS
  • SINUS RHYTHM
  • WARFARIN
  • OUTCOMES

Cite this